More About Kris
Kris Tatiossian, PhD, is the content lead, life sciences, on the Bio + Health team. She specializes in transforming complex scientific topics into accessible narratives. In this role, she oversees the brand’s digital strategy from podcasts, blogs, and newsletters to social media, bringing subjects like biotechnology and artificial intelligence to a broader audience. Working closely with different teams, Kris harmonizes the content creation journey from brainstorming to final delivery, ensuring that the brand message remains cohesive and relevant.
Before joining Bio + Health, Kris served as the Founder/CEO of CRISPR Classroom and President of Arkitekt Bio. These experiences provided her with a broad understanding of entrepreneurship, strategic communication, and educational outreach, skills she applies in her current position.
Kris holds a PhD in Medical Biology from the University of Southern California and a Bachelor of Science in Entomology from the University of California, Davis. Off the clock, she enjoys adding to her insect collection, camping, and cooking.
Latest Content
-
Jeff Margolis, founder of TriZetto, joins Julie Yoo, a16z Bio + Health general partner, to share the journey of building an iconic company in healthcare infrastructure. From the early days of managed care to creating a t...
-
Matt Wilsey, cofounder and CEO of Grace Science, joins Jorge Conde, Bio + Health general partner, to share the profound personal story of his daughter Grace's diagnosis with NGLY1 deficiency and how it catalyzed his journey to founding a biotech startup aimed at developing a cure for his daughter’s condition.
-
Carolyn Bertozzi, PhD, Director of Sarafan Stanford ChEM-H and professor at Stanford University, joins Jorge Conde, general partner at a16z Bio + Health.
-
In this episode, a16z partners Jorge Conde and Jay Rughani sit down with Sajith Wickramasekara, CEO and cofounder of Benchling, to unpack the evolution of Benchling from idea to transformative software platform.
-
Chris Ellis, CEO and Adam Stevenson, president, both cofounders of Thatch, join Julie Yoo and Jay Rughani of a16z Bio + Health.
-
Jonathan Lim, chairman and CEO of Erasca, joins Jorge Conde, general partner at a16z. In a recent conversation, Lim shared valuable insights about his transition to the biotech world, his leadership experiences, and the lessons he's learned while founding and guiding organizations through high-stakes decision making.
-
Vijay Pande, general partner, and Daisy Wolf, investing partner, join host Steph Smith on this crossover episode of the a16z podcast.
-
Marta Bralic Kerns, founder and CEO of Pomelo Care, joins Will Shrank, MD, a16z Bio + Health venture partner. Together, they talk about the innovator’s dilemma with building in the Medicaid space
-
Nikita Singareddy, cofounder and CEO of Fortuna Health, joins Will Shrank, MD, a16z Bio + Health venture partner. This is the second episode in our Medicaid Matters series.
-
Over the next three episodes, we’re going to talk about why Medicaid matters, and the potential for technology to make it easier for enrollees to access and utilize the program. Our first guest is Mark Smith, MD, Clinical Professor of Medicine at UCSF.
-
Vijay Pande, PhD, founding partner of a16z Bio + Health, joins Derrick Harris, host of the AI + a16z podcast.
-
Casey Means, MD, a Stanford-trained physician, cofounder of Levels, and author of the new book Good Energy, joins Vijay Pande, PhD, founding partner of a16z Bio + Health.
-
Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb, or BMS, joins Jorge Conde, general partner at a16z. This is a follow-up to their 2023 episode, where they discussed how biopharma can adapt to AI.
-
Michael Crackower, PhD, Chief Scientific Officer of Ventus Therapeutics, and Jason Burch, PhD, join Vineeta Agarwala, PhD, general partner at a16z Bio + Health.
-
Bowen Liu, PhD, investing partner, and Surya Ganguli, PhD, venture partner, join Vijay Pande, PhD, general partner of a16z Bio + Health.
-
Bruce Levine, PhD, the Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, joins Jorge Conde, general partner, and Ginger Liau, partner at a16z Bio + Health.
-
In this episode, a follow-up to our episode Grand Challenges in Healthcare AI, Julie Yoo and Vijay Pande, a16z general partners, answer audience questions about AI applications in healthcare.
-
John Crowley, President and CEO of Biotechnology Innovation Organization (BIO), joins Jorge Conde, general partner at a16z Bio + Health.
-
Lawrence Ingrassia, author and journalist, joins Vineeta Agarwala, general partner, and Kris Tatiossian, editorial lead at a16z Bio + Health.
-
Jonathan Swerdlin, cofounder and CEO, and Mark Hyman, MD, cofounder and Chief Medical Officer of Function Health join Vijay Pande, general partner, and Daisy Wolf, investment partner of a16z Bio + Health.
-
Jonathan Bush, founder and CEO of Zus Health, and Chris Severn, cofounder and CEO of Turquoise Health, join Julie Yoo, general partner, and Colin Rom, head of public policy for a16z Bio + Health.
-
In this episode, originally recorded for the a16z Podcast, host Steph Smith interviews Pushmeet Kohli, DeepMind's VP of Research focused on AI for science. They are joined by a16z Bio + Health founding partner Vijay Pand...
-
Chronis Manolis, SVP and Chief Pharmacy Officer of UPMC Health Plan, joins Julie Yoo, general partner, Daisy Wolf, investment partner, and Will Shrank, venture partner, of a16z Bio + Health.
-
Brooke Boyarsky Pratt, founder and CEO of knownwell, joins Vineeta Agarwala, general partner at a16z Bio + Health.
-
As Ozempic, Wegovy, Mounjaro, and Zepbound capture the healthcare spotlight, we’ve developed a series of episodes that go beyond the headlines and take you into conversations with the specialists. Our first guest is Carolyn Jasik, MD, Chief Medical Officer at Omada Health.
-
Vineeta Agarwala, MD, PhD, joins Luke Timmerman's The Long Run podcast on stage at the Life Science Innovation Northwest Conference.
-
Kim Branson, PhD, SVP and Global Head of AI and Machine Learning for GSK, joins Vijay Pande, founding partner at a16z Bio + Health. Together, they talk about how AI has improved drug discovery and development, as Kim walks through all the ways AI can be deployed in the lab.
-
Tom Hale, CEO of ŌURA, joins Vijay Pande, founding partner, and Daisy Wolf, investment partner at a16z Bio + Health.
-
Philip Tagari, Chief Scientific Officer of insitro, joins Vijay Pande, founding general partner at a16z Bio + Health.
-
Vijay Pande, founding general partner of a16z Bio + Health, chats with the builders (and siblings) behind Devoted Health, Ed and Todd Park.
-
Vijay Pande, founding general partner, and Julie Yoo, general partner at a16z Bio + Health, come together to talk through the grand challenges facing healthcare AI today.
-
This episode features interviews with payor and provider leaders about what they’re seeing and how they’re thinking about AI. Guided by Julie Yoo, general partner, and Jay Rughani, investment partner at a16z Bio + Health, you'll hear from the executives about how they're utilizing AI, the KPIs they use to gauge effectiveness, and what they consider to be a good partnership.
-
Vijay Pande, founding general partner at a16z Bio + Health, joins the Software Engineering Daily podcast to talk about innovation in biotech and healthcare, the biotech startup landscape, the impact of AI, and much more.
-
Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health.
-
Vijay Pande, founding partner of a16z Bio + Health, dives deep with a16z Podcast host Steph Smith into the potential of DNA as a data storage mechanism.
-
Julie Klapstein, founding CEO of Availity, long-time healthcare executive, and a16z Bio + Health's newest advisory partner, joins Julie Yoo, general partner at a16z Bio + Health.
-
Scribe Therapeutics cofounder and CEO Ben Oakes joins a16z Bio + Health founding general partner Vijay Pande.
-
Josh Clemente, cofounder and president of Levels, joins Vijay Pande, founding general partner, and Daisy Wolf, investment partner at a16z Bio + Health.
-
Former gymnast and current investor Aly Raisman joins general partner Julie Yoo and investment partner Daisy Wolf of a16z Bio + Health.
-
Max Cohen, cofounder and CEO of Sprinter Health, and Eren Bali, founder and CEO of Carbon Health, join Julie Yoo, general partner at a16z Bio + Health.
-
In this episode, Joe Grogan, a senior fellow at the Leonard D. Schaeffer Center for Health Policy and Economics and a former senior government official, joins Vijay Pande, founding partner of a16z Bio + Health to discuss all things regulation.
-
Today's episode features the cofounders of Tome Biosciences, Rahul Kakkar, CEO of Tome, and John Finn, CSO. They are joined by Jorge Conde, general partner at a16z Bio + Health.
-
Vijay Pande, founding partner of Bio + Health, is joined by Daphne Koller, Andrew Ng, Aviv Regev, and Jakob Uszkoreit. Vijay leads us on a reflective journey through the monumental achievements in AI from the 1980s to today, with a focus on the progress in healthcare and life sciences.
-
Bio Eats World is now Raising Health! On this first episode of Raising Health, Sean Duffy, cofounder and CEO of Omada Health, joins Vijay Pande, founding partner of Bio + Health.
-
Today, we refocus these efforts and expand on them to give you Raising Health. That’s right, Bio Eats World is now Raising Health. While Bio Eats World had a focus on (bio)technological advancements, Raising Health zooms out, focusing not only on the tech, but also the people building it.
-
Pranav Rajpurkar, PhD, joins Vijay Pande, founding partner of a16z Bio + Health. In this episode, Pranav and Vijay discuss a future with generalist medical AI. This is the idea of a medical AI that isn’t narrowly tailored to one specific task.
-
Today’s landmark approval by the US Food and Drug Administration of Vertex Pharmaceuticals’ and CRISPR Therapeutics’ EXA-cell, the world’s first CRISPR-based treatment, marks a groundbreaking shift in how we tackle intractable diseases.
-
Jordi Mata-Fink, PhD, cofounder of Gate Bioscience, joins Vineeta Agarwala and Ben Portney of a16z Bio + Health.In this episode, Jordi discusses how he and his cofounders are working to commercialize a novel class of therapeutics, termed "molecular gates."
-
Mario Schlosser, cofounder, former CEO, and current President of Technology at Oscar Health, joins Julie Yoo of Bio + Health. The conversation explores how AI advancements can revolutionize traditional healthcare models by enhancing efficiency, personalizing care journeys, and integrating real-time data insights.
-
Miriam Vogel, President and CEO of EqualAI, cohost of the podcast In AI we Trust, and Chair to the recently launched National AI Advisory Committee, joins Vijay Pande of Bio + Health.
-
AI trailblazer Suchi Saria, PhD, in conversation with Vijay Pande, sheds light on the winding path that led her to launch Bayesian Health, a bold effort to infuse intelligence into clinical workflows.
-
In this candid conversation, Li unfolds her transformation from a young immigrant to an influential figure in AI. The conversation explores the birth of ImageNet, a pivotal step that bridged the gap between visual intelligence and accessible AI technology.
-
Together, they talk about how Evan’s work in the lab (ironically, Vijay's lab at Stanford!) translated to the creation of Genesis, which is tackling the problem of drug discovery through AI. They also discuss how the Genesis team is building specifically to carry on work at the intersection of ML, biotech, and chemistry.
-
Olga Troyanskaya, PhD, a professor in the department of computer science at Princeton and Deputy Director for Genomics at the Flatiron Institute's Center for Computational Biology, joins Vijay Pande, founding partner of a16z Bio + Health.
-
As Julie mentions during the episode, there’s international relations, and then there’s CMO/CPO relations. Peter and Reena talk about working together to improve their relationship and the outcomes of their teams, and they get granular about what worked and what didn’t.
